Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Other Accumulated Expenses (2016 - 2025)

Fate Therapeutics filings provide 13 years of Other Accumulated Expenses readings, the most recent being $4.4 million for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 30.62% to $4.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.4 million, a 30.62% decrease, with the full-year FY2025 number at $4.4 million, down 30.62% from a year prior.
  • Other Accumulated Expenses hit $4.4 million in Q4 2025 for Fate Therapeutics, up from $3.9 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $19.2 million in Q4 2022 to a low of $3.9 million in Q3 2025.
  • Median Other Accumulated Expenses over the past 5 years was $8.4 million (2023), compared with a mean of $9.9 million.
  • Biggest five-year swings in Other Accumulated Expenses: soared 183.19% in 2021 and later plummeted 63.72% in 2025.
  • Fate Therapeutics' Other Accumulated Expenses stood at $11.7 million in 2021, then soared by 63.75% to $19.2 million in 2022, then tumbled by 57.66% to $8.1 million in 2023, then dropped by 21.67% to $6.4 million in 2024, then plummeted by 30.62% to $4.4 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $4.4 million (Q4 2025), $3.9 million (Q3 2025), and $4.9 million (Q2 2025) per Business Quant data.